1 Litzow MR et al. Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial. Blood 2022;140(Supll_2):LBA-1
2 Litzow MR et al. Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults. N Engl J Med. 2024;391(4):320-333
3 Wedekind S. Neuer Therapiestandard bei MRD-negativer B-ALL: Konsolidierung mit Blinatumomab. Im Fokus Onkol 2023;26(1):28-29
4 Urbino I et al. Blinatumomab consolidation for adult B-cell acute lymphoblastic leukemia in first and second complete remission. Blood Adv. 2024;8(10):2405-9
5 Jabbour E et al. Blinatumomab Alternating With Low-Intensity Chemotherapy (CT) Treatment for Older Adults With Newly Diagnosed Philadelphia (Ph)-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) is Well Tolerated and Efficacious: Safety Run-In Results for the Phase 3 Randomized Controlled Golden Gate Study. Blood 2022;140 (Suppl_1):6134–6
6 https://www.ema.europa.eu/de/documents/product-information/blincyto-epar-product-information_de.pdf
